Boston Scientific agreed to acquire Valencia Technologies to add the implantable tibial nerve stimulation (eCoin) system to its pelvic‑health portfolio, citing complementary product fit and a move to broaden therapy options for overactive bladder. The company said the transaction will deepen category leadership in urology and pelvic health. Separately, market tallies show 2025 biopharma deal value climbed to a record near $293 billion, driven by late‑year blockbuster deals and collaborations. The combination of strategic M&A and high‑value partnerships signals sustained corporate appetite for portfolio expansion and acquisition of differentiated device and therapeutic platforms.